A phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen

[1]  L. Nguyen,et al.  Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks , 2006, Investigational New Drugs.

[2]  J. Machiels,et al.  A single arm, multicenter, open label, phase II study of lapatinib as 2L treatment of pts with locally advanced/metastatic transitional cell carcinoma (TCC) of the urothelial tract , 2005 .

[3]  M. Galsky,et al.  The impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients (pts) with transitional cell carcinoma (TCC) of the bladder , 2005 .

[4]  G. Peters,et al.  Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. , 2005, European journal of cancer.

[5]  M. Mencoboni,et al.  Single-Agent Gemcitabine in Previously Untreated Elderly Patients with Advanced Bladder Carcinoma: Response to Treatment and Correlation with the Comprehensive Geriatric , 2004, Oncology.

[6]  S. Culine,et al.  Clinical benefit of second line weekly paclitaxel in advanced urothelial carcinoma (AUC): A GETUG phase II study. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Manola,et al.  Phase III trial of methotrexate, vinblastine, doxorubicin, and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium , 2004, Cancer.

[8]  M. Dimopoulos,et al.  Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Stephanie Green,et al.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria , 1992, Investigational New Drugs.

[10]  S. Culine,et al.  844 A phase II study testing intravenous (iv) vinflunine (VFL) as second line therapy in patients with advanced transitional cell cancer (TCC) of the bladder , 2003 .

[11]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[12]  E. Raymond,et al.  Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  M. Vincenti,et al.  Higher antitumor activity of vinflunine than vinorelbine against an orthotopic murine model of transitional cell carcinoma of the bladder. , 2002, Urologic oncology.

[14]  S. Culine.  The present and future of combination chemotherapy in bladder cancer. , 2002, Seminars in oncology.

[15]  J. Gutheil,et al.  Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  P. Albers,et al.  Gemcitabine Monotherapy as Second-Line Treatment in Cisplatin-Refractory Transitional Cell Carcinoma – Prognostic Factors for Response and Improvement of Quality of Life , 2002, Oncology Research and Treatment.

[17]  P. Albers,et al.  Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  F. Colpaert,et al.  Superior in vivo experimental antitumour activity of vinflunine, relative to vinorelbine, in a panel of human tumour xenografts. , 1999, European journal of cancer.

[19]  V. Gebbia,et al.  Single agent 2',2'-difluorodeoxycytidine in the treatment of metastatic urothelial carcinoma: a phase II study. , 1999, La Clinica terapeutica.

[20]  G. Luporini,et al.  A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum , 1998 .

[21]  F. Colpaert,et al.  Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated Vinca alkaloid , 1998, Cancer Chemotherapy and Pharmacology.

[22]  I. Tannock,et al.  Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Kuzel,et al.  Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Pronzato,et al.  Second line chemotherapy with ifosfamide as outpatient treatment for advanced bladder cancer. , 1997, American journal of clinical oncology.

[25]  M. Mazumdar,et al.  Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Dreicer,et al.  Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Johnson,et al.  Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter. , 1997, British Journal of Cancer.

[28]  I. Tannock,et al.  A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  N. Geller,et al.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. , 1988, The Journal of urology.

[30]  T R Fleming,et al.  One-sample multiple testing procedure for phase II clinical trials. , 1982, Biometrics.

[31]  M. Palmer,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1982, British Journal of Cancer.

[32]  R. D. Hunter,et al.  WHO Handbook for Reporting Results of Cancer Treatment , 1980 .